Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Epidermal growth factor‐induced COX‐2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin‐like 4

(2020) Kuo‐Hwa Chiang et al.   CANCER SCIENCE

Phase II Study of Low‐Dose Afatinib Maintenance Treatment Among Patients with EGFR ‐Mutated Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 ( NJLCG1601 )

(2020) Atsushi Nakamura et al.   ONCOLOGIST

Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

(2019) Barbara Burtness et al.   JAMA Oncology

Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases

(2019) Philipp Jurmeister et al.   Science Translational Medicine

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

(2019) Y Guo et al.   ANNALS OF ONCOLOGY

Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)

(2018) J -P Machiels et al.   ANNALS OF ONCOLOGY

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations

(2018) Hisashi Tanaka et al.   MEDICAL ONCOLOGY

Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study)

(2018) Akito Hata et al.   CANCER

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial

(2016) P. M. Clement et al.   ANNALS OF ONCOLOGY

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

(2016) Keunchil Park et al.   LANCET ONCOLOGY

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)

(2016) Jacques De Grève et al.   PLoS One

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

(2015) M. Schuler et al.   ANNALS OF ONCOLOGY

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours

(2015) Rastislav Bahleda et al.   BRITISH JOURNAL OF CANCER

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

(2015) J. Y. Lee et al.   CLINICAL CANCER RESEARCH

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

(2015) Jean-Pascal H Machiels et al.   LANCET ONCOLOGY

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

(2015) Jean-Charles Soria et al.   LANCET ONCOLOGY

2014 FDA drug approvals

(2015) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†

(2014) T. Y. Seiwert et al.   ANNALS OF ONCOLOGY

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

(2014) D. A. Reardon et al.   NEURO-ONCOLOGY

Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials

(2014) Brennan C Kahan et al.   Trials

A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors

(2013) J. B. Vermorken et al.   ANNALS OF ONCOLOGY

Afatinib: First Global Approval

(2013) Rosselle T. Dungo et al.   DRUGS

Afatinib in the treatment of head and neck squamous cell carcinoma

(2013) Renata Ferrarotto et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

A PRISMA assessment of the reporting quality of systematic reviews in orthodontics

(2012) Padhraig S. Fleming et al.   ANGLE ORTHODONTIST

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

(2012) Vincent A Miller et al.   LANCET ONCOLOGY

Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios

(2011) Helen Barraclough et al.   Journal of Thoracic Oncology

Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach

(2011) Thomas M. Kessler et al.   PLoS One

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas

(2009) Satoshi Shiono et al.   ANNALS OF THORACIC SURGERY